Chaiwerawattana Arkom, Thanasitthichai Somchai, Boonlikit Sarawan, Apiwanich Chanin, Worawattanakul Suvipapan, Intakawin Anothai, Rakiad Supattra, Thongkham Kanchana
Breast Unit, Division of Surgery, National Cancer Institute, Thailand.
Asian Pac J Cancer Prev. 2012;13(8):4063-6. doi: 10.7314/apjcp.2012.13.8.4063.
To determine the clinical outcome of breast cancer BI-RADS 4 lesions and seek a more effective management guideline, we conducted a retrospective study of all BI-RADS4 patients diagnosed between 2003-2008 with follow up time not less than 2 years. A total of 392 cases of BI-RADS 4 were identified and 320 could be sub-categorised as 4a, 4b and 4c. Overall malignant positive results were 7.65, 38.7 and 58.percent, respectively. In all cases assigned to the close follow up group, no malignancy was detectable (P<0.02). The results of the study suggested that BI-RADS sub-categories have benefit for cancer diagnosis and treatment decisions of clinicians and it might be possible to set up a safe follow-up guideline in selected groups of patients to minimize un-necessary tissue biopsy for breast cancer detection.
为了确定乳腺影像报告和数据系统（BI-RADS）4类病变的临床结局并寻求更有效的管理指南，我们对2003年至2008年间诊断为BI-RADS 4类且随访时间不少于2年的所有患者进行了一项回顾性研究。共识别出392例BI-RADS 4类病例，其中320例可细分为4a、4b和4c类。总体恶性阳性结果分别为7.65%、38.7%和58%。在所有归入密切随访组的病例中，均未检测到恶性病变（P<0.02）。研究结果表明，BI-RADS亚类有助于临床医生进行癌症诊断和治疗决策，并且有可能在特定患者群体中建立安全的随访指南，以尽量减少用于乳腺癌检测的不必要组织活检。
